Regeneron drug highly effective for those who can't take statins -study
November 17, 2014 at 11:45 AM EST
CHICAGO, Nov 17 (Reuters) - Regeneron Corp's experimental drug alirocumab helped 10 times as many high-risk patients unable to tolerate widely-used statins get their "bad" LDL cholesterol down to target levels than Merck & Co's Zetia, according to data from a clinical trial presented on Monday.